Drug intelligence / Profile preview

Sudan virus GP vaccine

Development stage: Preclinical
Lead developer: Hawaii Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Sudan virus GP vaccine is a **recombinant subunit protein vaccine** being developed by **Hawaii Biotech** for prevention of **Sudan virus disease**, a filoviral hemorrhagic fever. The vaccine is designed around the **Sudan virus glycoprotein**, the major viral surface antigen responsible for host-cell attachment and entry, with the goal of inducing protective humoral and cellular immune responses against Sudan virus infection. Based on the provided company pipeline information, the program is in **preclinical development**.

Other names: sudan virus glycoprotein vaccineSudan virus glycoprotein GP vaccine

Targets

Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on Sudan virus GP vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sudan virus GP vaccine.

Explore the full profile